Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting.

Autor: Falchero L; Respiratory Medicine Department, Hopitaux Nord-Ouest, Villefranche-Sur-Saône, France. Electronic address: lfalchero@hno.fr., Meyer N; Public Health Department, CHU de Strasbourg, GMRC, Strasbourg, France., Molinier O; Respiratory Medicine Department, Centre Hospitalier Le Mans, Le Mans, France., Al Freijat F; Respiratory Medicine Department, Hôpital Nord Franche-Comté, Belfort, France., Pegliasco H; Respiratory Medicine Department, Hôpital Européen Marseille, Marseille, France., Lecuyer E; Respiratory Medicine Department, Centre Hospitalier de Saint-Quentin, Saint-Quentin, France., Stoven L; Respiratory Medicine Department, Centre Hospitalier de Boulogne-sur-Mer, Boulogne-sur-Mer, France., Belmont L; Respiratory Medicine Department, Centre Hospitalier d'Argenteuil, Argenteuil, France., Loutski S; Respiratory Medicine Department, Groupe Hospitalier Public du Sud de l'Oise (GHPSO), Creil, France., Maincent C; Respiratory Medicine Department, Centre Hospitalier Princesse Grace (GHPG), Monaco., Blanchet-Legens AS; Respiratory Medicine Department, Hôpital Saint Joseph Saint Luc, Lyon, France., Mairovitz A; Respiratory Medicine Department, Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges, Villeneuve-Saint-Georges, France., Meniai F; Respiratory Medicine Department, Centre Hospitalier de Calais, Calais, France., Hominal S; Respiratory Medicine Department, Centre Hospitalier Annecy Genevois, Pringy, France., Letierce A; QualityStat, Morangis, France., Morel H; Respiratory Medicine Department, Centre Hospitalier Régional D'Orléans Hôpital de La Source, Orléans, France., Debieuvre D; Respiratory Medicine Department, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, Hôpital Emile Muller, Mulhouse, France.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Oct; Vol. 210, pp. 114277. Date of Electronic Publication: 2024 Aug 14.
DOI: 10.1016/j.ejca.2024.114277
Abstrakt: Background: The KBP studies are real-life nationwide, prospective, multicenter cohort studies of patients diagnosed with primary lung cancer that have been conducted in French non-academic public hospitals each decade since 2000.
Methods: Patients were analyzed in three prospective cohorts using the same methodology. In this study, we describe and compare the characteristics and outcomes of patients with small cell lung cancer (SCLC), with a focus on treatments in the 2020 cohort.
Findings: 8999 patients with lung cancer were included in the 2020 cohort, of whom 1137 had SCLC. From 2000 to 2010 and 2020, the proportion of patients with SCLC decreased from 16.4 % to 13.5 % and 12.6 % respectively. Between 2000 and 2020, the proportion of women increased from 15.5 % to 35.7 %. 15.4 % of patients with SCLC had limited-stage (LS) disease and 84.6 % of patients had extensive-stage (ES) disease. The 1-year overall survival (OS) rate for all patients with SCLC increased from 34.4 % in 2000 to 38.4 % in 2020. For ES-SCLC, multivariate analysis weighted with "entropy balancing" by including age, sex, performance status, number of metastatic sites, and brain metastases indicated an improvement in median OS from 8.1 months in patients receiving chemotherapy only to 11.1 months in patients receiving chemotherapy plus immunotherapy (HR 0.62, p < 0.001).
Interpretation: The proportion with SCLC has decreased over time, but the proportion of women has increased. The 1-year OS rates have improved over 20 years. The KBP-2020 cohort suggests a benefit of immunotherapy on OS in patients with ES-SCLC in the real-life setting.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: